Ranbaxy Excludes One-off Gains In Altered Sales Guidance As Guessing Game Continues On Valsartan
This article was originally published in PharmAsia News
Executive Summary
The Indian drug maker came out with subdued third quarter numbers in the face of adverse conditions in its home market. However, Ranbaxy has kept its hopes pinned on potential upsides in the U.S. from products like valsartan.